Illimis Therapeutics Secures $42 Million to Advance CNS Drug Development
Illimis Therapeutics has successfully closed a Series B financing round, securing approximately 58 billion KRW ($42 million) to enhance its drug development efforts targeting central nervous system (CNS) and immune…